{{short description|Potential vaccine or vaccines against COVID-19}}
[[File:COVID-19 vaccine map.svg|thumb|right|400px|
ဗီုတိ မထ္ၜး ဍုင်မပဒတန် ဝက်သိန်ဂမၠိုင်
{{legend|Green|Approved for general use, mass vaccination underway}}
{{legend|SpringGreen|[[:w:Emergency Use Authorization|{{abbr|EUA|emergency use authorization}}]] granted, mass vaccination underway}}
{{legend|DarkOrange|{{abbr|EUA|emergency use authorization}} granted, limited vaccination}}
{{legend|Blue|Approved for general use, mass vaccination planned}}
{{legend|DodgerBlue|{{abbr|EUA|emergency use authorization}} granted, mass vaccination planned}}
{{legend|Gold|{{abbr|EUA|emergency use authorization}} pending}}]]

'''ဝက်သိန် ကဝ်ဝိဒ်-၁၉'''  ({{Lang-en| '''COVID‑19 vaccine'''}}) ဂှ် ဒှ် ဝက်သိန် မပကဵု ညံင်[[ဒြဟတ်အိမ်မုန်]]မသ္ဂောအ်တီ သွက်ဂွံဒစဵုဒစး ယဲကဝ်ဝိဒ်-၁၉။ ကိုပ်ကၠာ ကပ်ယဲကဝ်ဝိဒ်-၁၉ ဟွံကတဵုဒှ်ဏီဂှ်ရ၊ တၠပညာတအ် ကၠောန်ပ္တိတ်လဝ် ဝက်သေန် သွက်ဂွံဗတိုက် ကဝ်ရဝ်နာဝဳရုသ် မပကဵု ညံင်ဂွံဒှ်ယဲသာ (SARS) ကေုာံ ယဲမာ (MERS)တုဲ တၠပညာတအ် တီကၠိုဟ်လဝ် ပရူလဒက်ပ္တန် ကေုာံ တၠုင်လအာ ကဝ်ရဝ်နာဝဳရုသ်တုဲ ကာလ ကဝ်ရဝ်နာဝဳရုသ်ဂကူတၞဟ် မပကဵု ညံင်ဂွံဒှ် ယဲကဝ်ဝိဒ်-၁၉ ကတဵုဒှ် ပ္ဍဲတမ်သၞာံ ၂၀၂၀ ဂှ် ညးတအ် ဂစာန်ကၠောန် ဝက်သိန်-ကဝ်ဝိဒ်-၁၉။ 

စိုပ်ၜိုတ် လဒေါဝ်ဒဳဇြေမ်ဗါ ၂၀၂၀ ဂှ် လၟောဝ်ဝက်သိန် ၅၇ ဂှ် ဂစာန်ကၠောန် ပဒၟံင်သုတေသနဂဥုဲတုဲ ပၞောဝ်တအ်ဂှ် ၄၀ ဂှ် နွံဒၟံင် ကဆံင်ကာလစွမ် ပထမ - ဒုတိယတုဲ ၁၇ ဂှ် နွံဒၟံင် ကဆံင်ကာလစွမ် ဒုတိယ - တတိယ။ ပ္ဍဲကဆံင်ကာလစွမ်တတိယဂှ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉ ဗွဲမဂၠိုင် ကၠောန်ကမၠောန် ၜိုတ် ၉၅% သွက်ဂွံစဵုဒၞာ ယဲကဝ်ဝိဒ်-၁၉။<ref>{{Cite web|last=Santiago|first=Jahleah|date=2020-12-19|title=A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines|url=https://www.statnews.com/2020/12/19/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-vaccines/|url-status=live|archive-url=|archive-date=|access-date=2020-12-24|website=STAT|language=en-US}}</ref> ဝက်သိန်လ္ၚဵုတအ်ဂှ် ဍုင်လ္ၚဵု ပဒတန်တုဲ ဝက်သိန်လ္ၚဵုတအ်ဂှ် ဍုင်လ္ၚဵုဟွံပဒတန်ရ။ သီုဖအိုတ် မဂွံဒုင်ပဒတန် နကဵု အေဂျေန်သဳ ထတ်ယုက်ဍုင်တအ်ဂှ် နွံ မသုန် မပ္တံကဵု တဝ်ဇြဳနာမေရန် (Tozinameran) မကၠောန်ပ္တိတ် နူကဵု ဖြိဇြေရ်-ဗဳသြတေက် (Pfizer–BioNTech)၊ ဗဳဗဳဗ်-ကောဝ် (BBIBP-CorV) မကၠောန်ပ္တိတ် နူကဵု သဳနဝ်ဖာမ် (Sinopharm)၊ ကဝ်ရဝ်နာဝက် (CoronaVac) မကၠောန်ပ္တိတ် နူကဵု သဳနဝ်ဝက် (Sinovac)၊ အာမ်အာနာ-၁၂၇၃ (mRNA-1273) မကၠောန်ပ္တိတ် နူကဵု မဝ်ဒေရ်နာ (Moderna) ကေုာံ ဂမ်-ကဝ်ဝိဒ်-ဝက် (Gam-COVID-Vac) မကၠောန်ပ္တိတ် နူကဵု  အေန်သတဳကျုတ်သုတေသနဂမလေယာ (Gamaleya Research Institute)။ 

ဖြိဇြေရ်၊ မဝ်ဒေရ်နာ ကေုာံ သြသတြဇြေနေက (AstraZeneca) တအ် ဟီုလဝ် ပ္ဍဲသၞာံ ၂၀၂၁ မ္ဂး ညးတအ် ကၠောန်ပ္တိတ် လၟိဟ် ၅.၃&nbsp;ဗဳလဳယာန် သွုင် မာန်တုဲ ကလိဂွံ မၞိဟ်ၜိုတ် ၃ ဗဳလဳယာန်မာန် (မၞိဟ်မွဲမ္ဂး ဒးထ္ပက် ၂ သွုင်/တၞိင် သွက်ဂွံစဵုဒၞာ ကဝ်ဝိဒ်-၁၉)၊ ပ္ဍဲဂိတုဒဳဇြေမ်ဗါဂှ် နူကဵု ဍုင်နာနာတအ် ဗကန်လဝ် နူကဵုဌာနပ္တိတ်ဝက်သိန်တအ် လၟိဟ် ၁၀ ဗဳလဳယာန်ပြင်င်<ref name="mullard">{{cite journal|first1=Asher | last1=Mullard |date=30 November 2020|title=How COVID vaccines are being divvied up around the world Canada leads the pack in terms of doses secured per capita|url=https://www.nature.com/articles/d41586-020-03370-6|journal=Nature|doi=10.1038/d41586-020-03370-6|pmid=33257891|access-date=11 December 2020|s2cid=227246811}}</ref> ကဝက်ပြင်င်ဂှ် ဍုင်ပိုန်ဒြပ်ဇၞော်မောဝ်တအ် ဗကန်လဝ်တုဲ ဟီုကဵုလၟိဟ်မၞိဟ်ဂၠးကဝ်မ္ဂး ဍုင်သေဋ္ဌဳတအ်ဂှ် လၟိဟ်မၞိဟ် နွံ ၁၄% ဓဝ်ရ။<ref name="So">{{cite journal|last=So|first=Anthony D|last2=Woo|first2=Joshua|date=December 2020|title=Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis|journal=BMJ|page=m4750|doi=10.1136/bmj.m4750|issn=1756-1833|name-list-style=vanc|doi-access=free}}</ref> ဍုင်ဗွဲမဂၠိုင်တအ်ဂှ် ဖျေဟ်လၟေင်ကမၠောန် ထပက်ဝက်သိန် နကဵု မၞိဟ်ဗယု၊ ယဲဇမၠိင် မဒှ်မၞိဟ်အန္တရာယ်ဇၞော် ကုယဲကဝ်ဝိဒ်-၁၉ ကေုာံ အစာဂဥုဲ အစာသဝ်ဂှ် ကဵုထ္ပက်ကၠာရ။<ref>{{Cite news|last=Beaumont|first=Peter|date=2020-11-18|title=Covid-19 vaccine: who are countries prioritising for first doses?|language=en-GB|work=The Guardian|url=https://www.theguardian.com/world/2020/nov/18/covid-19-vaccine-who-are-countries-prioritising-for-first-doses|access-date=2020-12-26|issn=0261-3077}}</ref>

==လၟေင်ကမၠောန် ကေုာံ ဓလိုက်တမ်ရိုဟ်==
ပ္ဍဲမွဲဒမြိပ်သၞာံ ၂၀၂၀ နူစ သၞာံမံက်၊ ယဲကပ်စကတဵုဒှ်ဂှ် ဌာနမကၠောန်ပ္တိတ်ဂဥုဲဂမၠိုင်၊ အလဵုအသဳဍုင် ကေုာံ ကမ္မဏဳမဆေင်ကဵုဇဳဝဗေဒ နူကဵု ရးနိဂီုနာနာ ပ္တိတ်အာရီု ဂစာန်ကၠောန်ကၠုင် သွက်ကလိဂွံ ဝက်သိန်ကဝ်ဝိဒ်-၁၉ အိုတ်ရ။<ref name="thanh2">{{cite journal|last1=Le|first1=Tung Thanh|last2=Cramer|first2=Jakob P.|last3=Chen|first3=Robert|last4=Mayhew|first4=Stephen|date=4 September 2020|title=Evolution of the COVID-19 vaccine development landscape|journal=Nature Reviews Drug Discovery|volume=19|issue=10|pages=667–68|doi=10.1038/d41573-020-00151-8|issn=1474-1776|pmid=32887942|doi-access=free|s2cid=221503034|name-list-style=vanc}}</ref> အတိုင် ဂကောံပံင်ကောံမခၞံဗဒှ်သွက်စဵုဒၞာကပ်ယဲ (Coalition for Epidemic Preparedness Innovations -CEPI) မဗမံက်ထ္ၜးလဝ်မ္ဂး ဂကောံမပါလုပ် ပ္ဍဲအရာမကၠောန်ပ္တိတ် ဝက်သိန်ဏအ်ဂှ် နူကဵု အမေရိသၟဝ်ကျာဂှ် ၜိုတ် ၄၀%၊ အာရှ ကဵု အဝ်သတြေလျာ ၃၀%၊ ဥရောပ ၂၆% တုဲ ပ္ဍဲအမေရိသၠုင်ကျာ ကဵု အာဖရိကဂှ် ပါလုပ်ညိညကီုရ။<ref name="thanh2" /><ref name="thanh" />

လၟောဝ်ဝက်သိန်မွဲမွဲ ဂွံကလိဂွံဇမၞးမာန်ဂှ် ဒးအိုတ်သြန် ဗွဲမဂၠိုင်ဂၠေင်ရ။ ဥပမာ ခရိတ်င္ၚုဟ်အိုတ် ပ္ဍဲ ကာလစွမ်မၞိဟ်အလန်ပထမဂှ်သၟးဂှ် ဒးအိုတ် သြန်ဒဝ်လာအမေရိကာန် အကြာ ၁၄ မဳလဳယာန်ကဵု  ၂၅ မဳလဳယာန်။<ref name="gouglas">{{cite journal|vauthors=Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA|date=December 2018|title=Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study|journal=Lancet Global Health|volume=6|issue=12|pages=e1386–96|doi=10.1016/S2214-109X(18)30346-2|pmc=7164811|pmid=30342925}}</ref><ref name="dimasi">{{cite journal|vauthors=DiMasi JA, Grabowski HG, Hansen RW|date=May 2016|title=Innovation in the pharmaceutical industry: New estimates of R&D costs|journal=Journal of Health Economics|volume=47|pages=20–33|doi=10.1016/j.jhealeco.2016.01.012|pmid=26928437|doi-access=free|hdl-access=free|hdl=10161/12742}}</ref> ယဝ်ဒးပတုပ် နကဵုဥပမာမ္ဂး အခိင်ကာလ ကပ်ယဲအဳဗဝ်လာဝဳရုသ် (Ebola virus) မကတဵုဒှ် အကြာ ၂၀၁၃-၁၆ ဂှ် လၟောဝ်ဝက်သိန် သီုဖအိုတ် ဂစာန်ကၠောန် ၃၇ ဂှ် ဆဝက်သိန်မွဲဟေင် ကလိဂွံအခေါင်လာင်ဇြေန် သွက်ဂွံစကာ နဒဒှ် ဝက်သိန်၊ ညးမပ္တိတ်ဂှ် ခရိတ်စမ် ကာလစွမ်ဒုတိယ-တတိယဂှ် ဒးစကာသြန် ဒဝ်လာအမေရိကာန် ၜိုတ် ၁ ဗဳလဳယာန်။<ref name="gouglas"/>

=== ဂကောံ ရးနိဂီုနာနာ ===

====Access to COVID-19 Tools (ACT) Accelerator ကေုာံ COVAX====

ပရေင်ပံင်ကောံ ဂကောံဂၠးကဝ်နာနာ မပ္တံကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် (WHO)၊ ဂကောံပံင်ကောံ သွက်ဂၠိုက်ဂၠာဲ အရာမဒစဵုဒစး ကပ်ယဲ(CEPI)၊ GAVI၊ Gates Foundation ကေုာံ သၟိင်ဍုင်ဂမၠိုင် ပံင်ကောံတုဲ ဒက်ပ္တန်လဝ် အေသဳတဳ (ACT) မဂွံအဓိပ္ပါယ် ကလိဂွံ ကပေါတ်သွက်ယဲကဝ်ဝိဒ်-၁၉ တအ် ပံင်ကောံတုဲ ဂၠာဲသြန်ဗွဝ် သွက်ဂွံထံက်ပင် ကမၠောန်လ္ၚတ်သုတေသန၊ ပ္တိတ်ကပေါတ်စွမ်ယဲ၊ ဂဥုဲလွဳ ကေုာံ ကဵုလာင်ဇြေန်ဝက်သိန် မဒှ်ပရေင်ကမၠောန် နကဵုက္ဍိုပ်လိက် "ကဝ်ဝဇ် ပိလ္လာရ် (COVAX Pillar)"။<ref name="who-covax">{{Cite web|date=2020|title=What is the ACT Accelerator?|url=https://www.who.int/initiatives/act-accelerator/about|url-status=live|archive-url=https://web.archive.org/web/20200925122714/https://www.who.int/initiatives/act-accelerator/|archive-date=25 September 2020|access-date=2020-08-29|publisher=World Health Organization}}</ref><ref name="covax-gavi-09">{{cite web|date=2020-09-01|title=What is COVAX?|url=https://www.gavi.org/vaccineswork/covax-explained|access-date=11 December 2020|publisher=GAVI}}</ref> နကဵု ကဝ်ဝက်ပိလ္လာရ်ဂှ် စွံလဝ် တင်ရန်တၟအ် ညံင်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ကဝ်ဝိဒ်-၁၉ ဗွဲမဂၠိုင်တုဲ လအိတ်သၞာံ ၂၀၂၁ မ္ဂး ညံင်ဂွံပ္တိတ် စဵုကဵု ၂ ဗဳလဳယာန်သွုင် သွက်ဂွံစဵုဒၞာ သၟာကမၠောန်ထတ်ယုက် ပ္ဍဲကိုပ်စၞေဟ် (frontline healthcare workers) ကေုာံ မၞိဟ်အန္တရာယ်ဇၞော် ကုကဝ်ဝိဒ်-၁၉ ပ္ဍဲဍုင်ဒိုက်ဂတ်တအ်ရ။<ref name="cepi-covax">{{cite web |title=COVAX: CEPI's response to COVID-19|url=https://cepi.net/COVAX/ |publisher=Coalition for Epidemic Preparedness Innovations (CEPI) |access-date=15 December 2020 |date=2020}}</ref><ref name="cepi-safer">{{cite web |title=New vaccines for a safer world |url=https://cepi.net/ |publisher=CEPI |access-date=15 December 2020 |date=2020}}</ref>

ဂိတုဒဳဇြေမ်ဗါ ၂၀၂၀ ဂှ် နကဵုအေသဳတဳ ပ္ကောံဂွံသြန်ဒဝ်လာ ၂.၄ အမေရိကာန်ဒဝ်လာတုဲ နကဵု ကဝ်ဝက် ကေုာံ CEPI ဂွံဆဵုကေတ် လၟောဝ်ဝက်သိန် ဒစိတ် ရ။ ဂကောံဏအ်ဂှ် ဒှ်ဂကောံဇၞော်အိုတ် မဆေင်ကဵု ပ္ဍဲအရာမပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉တုဲ ပါလုပ်လဝ် သီုဖအိုတ် ဍုင် ၁၈၉ ရးနိဂီု။<ref name="cepi-portfolio">{{cite web |title=Our portfolio: partnerships to develop vaccines against COVID-19 |url=https://cepi.net/research_dev/our-portfolio/ |publisher=CEPI |access-date=15 December 2020 |date=2020}}</ref><ref name="who189">{{cite web|date=4 December 2020|title=Global equitable access to COVID-19 vaccines estimated to generate economic benefits of at least US$ 153 billion in 2020–21, and US$ 466 billion by 2025, in 10 major economies, according to new report by the Eurasia Group|url=https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21|access-date=11 December 2020|publisher=World Health Organization}}</ref> သၞာံ ၂၀၂၀ လပါ်စဂှ် နကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် ကလိဂွံ သြန်ထံက်ပင် နူကဵု ပန်စှ်ောဍုင် သြန်ဒဝ်လာအမေရိကာန် ၈ ဗဳလဳယာန် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ရ။<ref name="waked">{{Cite web|last=Wake|first=Damon|date=2020-05-04|title=EU spearheads $8 billion virus fundraiser|url=https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html|url-status=live|archive-url=https://web.archive.org/web/20200629033556/https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html|archive-date=29 June 2020|access-date=2020-05-04|publisher=Yahoo Finance|name-list-style=vanc}}</ref>

ဂိတုဂျူလာင်ဂှ် ဂကောံထတ်ယုက်ဂၠးကဝ် လလောင်တြး ဍုင် ၁၆၅ ဍုင် မပစၞးကု ကောန်မၞိဟ်ဂၠးတိ ၆၀% တုပ်စိုတ် အစဳအဇန်ကဝ်ဝက်တုဲ ကဵုလဝ် ဒုင်လဝ်ဂတိ တုပ်လဝ်စိုတ် ကၞောတ်သၞာံ ၂၀၂၁ မ္ဂး ကောန်ဍုင်ညးတအ် ၂၀% ဂှ် သ္ကလိဂွံ ဝက်သိန်ရောင်။<ref name="covax">{{cite press release |title=More than 150 countries engaged in COVID-19 vaccine global access facility |url=https://www.who.int/news-room/detail/15-07-2020-more-than-150-countries-engaged-in-covid-19-vaccine-global-access-facility |publisher=World Health Organization |access-date=25 July 2020 |date=15 July 2020 |quote=COVAX is the only truly global solution to the COVID-19 pandemic. For the vast majority of countries, whether they can afford to pay for their own doses or require assistance, it means receiving a guaranteed share of doses and avoiding being pushed to the back of the queue, as we saw during the H1N1 pandemic a decade ago. Even for those countries that are able to secure their own agreements with vaccine manufacturers, this mechanism represents, through its world-leading portfolio of vaccine candidates, a means of reducing the risks associated with individual candidates failing to show efficacy or gain licensure. |archive-date=15 July 2020 |archive-url=https://web.archive.org/web/20200715152301/https://www.who.int/news-room/detail/15-07-2020-more-than-150-countries-engaged-in-covid-19-vaccine-global-access-facility |url-status=live }}</ref>

ဂကောံပံင်ကောံဂၠးကဝ် သွက်စဵုဒၞာယဲကမၠောအ် (The Global Research Collaboration for Infectious Disease Preparedness - GLoPID-R) ဂှ် ပံင်တောဲကၠောန် ကုဂကောံထတ်ယုက်ဂၠးကဝ် ကေုာံ ရးနိဂီုဂမၠိုင် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉ရ။<ref>{{Cite web |title=GloPID: Novel coronavirus COVID-19 |url=https://www.glopid-r.org/our-work/novel-coronavirus-covid-19 |website=glopid-r.org |access-date=2020-05-02 |archive-url=https://web.archive.org/web/20200502035337/https://www.glopid-r.org/our-work/novel-coronavirus-covid-19/ |archive-date=2 May 2020 |url-status=live | quote =GloPID-R Members and other major players involved in infectious disease outbreaks worldwide reacted rapidly to this emerging epidemic, working closely with the WHO to identify the specific funding research priorities needed to tackle the disease. }}</ref><ref name=can-research/>တုဲပၠန် International Severe Acute Respiratory ကေုာံ Emerging Infection Consortium တအ်ဂှ် ဒှ်ဂကောံလ္ၚတ်မကဵုပရိုင်တင်ဂၞင် ပညာ ပ္ဍဲအရာမပသုတေသန ကဝ်ဝိဒ်-၁၉ ကေုာံ ကဵုပညာကုညးဍုင်ကွာန်တအ် သီုကဵု ပ္ဍဲအရာမပရးဝက်သိန်တအ်ရ။<ref name="isaric">{{Cite web|title=ISARIC: COVID-19 clinical research resources|url=https://isaric.tghn.org/covid-19-clinical-research-resources/|date=2020-04-27|publisher=ISARIC|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200330135638/https://isaric.tghn.org/covid-19-clinical-research-resources/|archive-date=30 March 2020|url-status=live}}</ref>

ပ္ဍဲ ၄ ဂျောန်ဂှ် ပူဂိုလ် ကေုာံ သၟိင်ဍုင်ဂမၠိုင် ကၠောန်ဗဒှ် ကောံဓရီုသကိုပ်သက သုမ္မိတ် (summit) ပ္ဍဲဍုင်လာန်ဒါန်၊ ယူကေ၊ ဂှ် မၞိဟ်နူ ၅၂ ဍုင်တိုန်စိုပ်၊ သကိုပ်သကဍုင် ၃၅ ဍုင်၊ နူကဵု ဂျဳ၇ တအ်ကီု သီုကဵု ဂျဳ၂၀ဂှ် ကလိဂွံ သြန်ဗွဝ် ၈ ဗဳလဳယာန် သွက်ဂွံထံက်ပင် မဟာမိတ်ဂၠးကဝ် သွက်ဝက်သိန် ကေုာံ အိမ်မုန် (Global Alliance for Vaccines and Immunisation - GAVI) သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉တုဲ ကဵုဂဥုဲဝက်သိန် ကုကောန်ၚာ် ၃၀၀ ဗဳလဳယာန် မနွံပ္ဍဲဍုင်ဒိုက်ဂတ်တအ် ပ္ဍဲအကြာသၞာံ ၂၀၁၅ ရ။<ref name="gavi-summit">{{Cite web|title=Global Vaccine Summit 2020: World leaders make historic commitments to provide equal access to vaccines for all|url=https://www.gavi.org/news/media-room/world-leaders-make-historic-commitments-provide-equal-access-vaccines-all|access-date=2020-06-04|publisher=Global Alliance for Vaccines and Immunisation|date=2020-06-04|archive-url=https://web.archive.org/web/20200606161748/https://www.gavi.org/news/media-room/world-leaders-make-historic-commitments-provide-equal-access-vaccines-all|archive-date=6 June 2020|url-status=live}}</ref>သြန်ဒါန် ဂၠိုင်အိုတ် ၁.၆ ဗဳလဳယာန် နူကဵု The Gates Foundation<ref>{{Cite press release |publisher=The Bill & Melinda Gates Foundation|via=PR Newswire|title=Bill & Melinda Gates Foundation pledges {{US$|1.6}}{{nbsp}}billion to Gavi, the Vaccine Alliance, to protect the next generation with lifesaving vaccines|url=https://www.prnewswire.com/news-releases/bill--melinda-gates-foundation-pledges-1-6-billion-to-gavi-the-vaccine-alliance-to-protect-the-next-generation-with-lifesaving-vaccines-301070878.html|access-date=2020-06-04|date=2020-06-04|archive-url=https://web.archive.org/web/20200604165907/https://www.prnewswire.com/news-releases/bill--melinda-gates-foundation-pledges-1-6-billion-to-gavi-the-vaccine-alliance-to-protect-the-next-generation-with-lifesaving-vaccines-301070878.html|archive-date=4 June 2020|url-status=live}}</ref> ကေုာံ သြန်ပံင်ဗြိတိန် ၃၃၀ မဳလဳယာန် ဇၟာပ်သၞာံ ပွိုင် မသုန်သၞာံ နူကဵု အလဵုအသဳဗြိတိန် (မတုပ်သၟဟ်ကဵု ဒဝ်လာအမေရိကာန် ၂.၁ ဗဳလဳယာန် ပ္ဍဲ ဂျောန် ၂၀၂၀)။<ref name=gavi-summit/>

ပ္ဍဲဒဳဇြေမ်ဗါ ဂှ် နကဵု Gates Foundation ဆက်ကဵုဒါန် သြန်ဒဝ်လာ ၂၅၀ မဳလဳယာန်ပၠန် သွက်ဂွံကဵု ကပေါတ်စွမ်ကဝ်ဝိဒ်-၁၉၊ လွဳယဲ ကေုာံ ဝက်သိန် သွက်ဍုင်ဒိုက်ဂတ် ပ္ဍဲသၞာံ ၂၀၂၁ တုဲ သြန်ဗွဝ်သီုဖအိုတ် ဒှ်အာ သြန်ဒဝ်လာအမေရိကာန် ၁.၇၅ ဗဳလဳယာန်။<ref name="gates12-10">{{cite news |first1=Haley | last1=Yamada |first2=Jon | last2=Schlosberg |first3=Seni | last3=Tienabeso |title=Bill and Melinda Gates Foundation announces $250 million COVID vaccine commitment |url=https://abcnews.go.com/Technology/bill-melinda-gates-foundation-announces-250-million-covid/story?id=74651890 |access-date=11 December 2020 |work=ABC News - Technology |date=10 December 2020}}</ref><ref name="gates12-9">{{cite news |title=Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world |url=https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/12/Bill-and-Melinda-Gates-call-for-collaboration-innovation-to-deliver-COVID-19-breakthroughs |access-date=11 December 2020 |work=Bill & Melinda Gates Foundation |date=9 December 2020}}</ref>

==ကမၠောန်==
===ဒဒှ်အတိက်===
ကိုပ်ကၠာ ကပ်ယဲကဝ်ဝိဒ်-၁၉ ဟွံကတဵုဒှ်ဏီဂှ် ဝက်သိန် သွက်စဵုဒၞာယဲဂှ် ဟွံဂွံကၠောန်ပ္တိတ် သၞာံဗွဲမလအ်ရ။ တုဲပၠန် ဝက်သိန် ဒစဵုဒစး ကဝ်ရဝ်နာဝဳရုသ် သွက်မၞိဟ်ဂှ်လေဝ် ဟွံကေင် နွံကၠုင်လဝ်ရ။<ref name="gates2" /> ဆဂး ဝက်သိန် ဒစဵုဒစး ကဝ်ရဝ်နာဝဳရုသ် သွက်တိရစ္ဆာန်ဂှ် ကေင်ပ္တိတ်လဝ်နွံ မပ္တံကဵု သၞာံ ၂၀၀၃ သွက်ဂစေံ၊ ကၠဵု ကေုာံ ဗ္ဂဲ။<ref>{{cite journal|vauthors=Cavanagh D|date=December 2003|title=Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus|journal=Avian Pathology|volume=32|issue=6|pages=567–82|doi=10.1080/03079450310001621198|pmc=7154303|pmid=14676007|doi-access=free}}</ref> တုဲပၠန် ဝိက်သိန် မဒစဵုဒစး ဝဳရုသ်ကဝ်ရဝ်နာ ဗဳဇမတုပ် မပကဵု ညံင်မၞိဟ်ဂွံဒှ်ယဲ သာ(SARS) ကေုာံ ယဲမာ(MERS)ကေင်နွံကၠုင်လဝ်ကီုရ။ ဝက်သိန် ဒစဵုဒစး ယဲသာ<ref>{{cite journal|display-authors=6|vauthors=Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A|date=December 2003|title=Effects of a SARS-associated coronavirus vaccine in monkeys|journal=Lancet|volume=362|issue=9399|pages=1895–96|doi=10.1016/S0140-6736(03)14962-8|pmc=7112457|pmid=14667748}}</ref> ကဵု ယဲမာ<ref>{{cite journal|display-authors=6|vauthors=Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A|date=October 2014|title=Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice|journal=Vaccine|volume=32|issue=45|pages=5975–82|doi=10.1016/j.vaccine.2014.08.058|pmc=7115510|pmid=25192975}}</ref>ဂှ်လေဝ် ဟွံကေင်စမ်လဝ် မၞိဟ် ဆစမ်လဝ် ကဵုတိရစ္ဆာန်သၟးရ။

အတိုင်လိက်မပ္တိတ်လဝ်မ္ဂး ပ္ဍဲသၞာံ ၂၀၀၅ ကဵု ၂၀၀၆ ဂှ် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကေုာံ ဂဥုဲလွဳယဲသာ ဒှ်လဝ် အရာကိစ္စဇၞော် သၟိင်ဍုင်တအ်ကီုရ။<ref name="PMID 15655773">{{cite journal|display-authors=6|vauthors=Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM|date=February 2005|title=Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice|journal=The Journal of Infectious Diseases|volume=191|issue=4|pages=507–14|doi=10.1086/427242|pmc=7110081|pmid=15655773}}</ref><ref name="PMID 15885812">{{cite journal|display-authors=6|vauthors=Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, Jones LP, Yilla M, Babcock GJ, Greenough T, Ambrosino DM, Alvarez R, Callaway J, Cavitt S, Kamrud K, Alterson H, Smith J, Harcourt JL, Miao C, Razdan R, Comer JA, Rollin PE, Ksiazek TG, Sanchez A, Rota PA, Bellini WJ, Anderson LJ|date=September 2005|title=Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins|journal=Journal of Virological Methods|volume=128|issue=1–2|pages=21–28|doi=10.1016/j.jviromet.2005.03.021|pmc=7112802|pmid=15885812}}</ref><ref name="PMID 16453264">{{cite journal|display-authors=6|vauthors=Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan JL, Zaki S, Subbarao K, Ambrosino DM|date=March 2006|title=Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters|journal=The Journal of Infectious Diseases|volume=193|issue=5|pages=685–92|doi=10.1086/500143|pmc=7109703|pmid=16453264}}</ref>ပ္ဍဲသၞာံ ၂၀၂၀ ဂှ် ဂဥုဲ ကေုာံ ဝက်သိန် သွက်ဂွံလွဳ ကေုာံ သွက်စဵုဒၞာ ယဲသာ ပ္ဍဲမၞိဟ် မကၠောန်ကမၠောန်ဇေတ်တ်ဂှ် ဟွံကလိဂွံ်ဏီရ။<ref name="JiangFutureVirology">{{cite journal|vauthors=Jiang S, Lu L, Du L|date=January 2013|title=Development of SARS vaccines and therapeutics is still needed|journal=Future Virology|volume=8|issue=1|pages=1–2|doi=10.2217/fvl.12.126|pmc=7079997|pmid=32201503}}</ref><ref>{{cite web|date=5 March 2020|title=SARS (severe acute respiratory syndrome)|url=https://www.nhs.uk/conditions/sars/|url-status=live|archive-url=https://web.archive.org/web/20200309174230/https://www.nhs.uk/conditions/sars/|archive-date=9 March 2020|access-date=31 January 2020|publisher=[[National Health Service]]}}</ref>

တုဲပၠန် ဝက်သိန် စဵုဒၞာယဲမာလေဝ် ဟွံမဲဏီကီုရ။<ref>{{cite journal|last1=Shehata|first1=Mahmoud M.|last2=Gomaa|first2=Mokhtar R.|last3=Ali|first3=Mohamed A.|last4=Kayali|first4=Ghazi|date=January 2016|title=Middle East respiratory syndrome coronavirus: a comprehensive review|journal=Frontiers of Medicine|volume=10|issue=2|pages=120–36|doi=10.1007/s11684-016-0430-6|pmc=7089261|pmid=26791756|name-list-style=vanc}}</ref> ကာလ ယဲမာကတဵုဒှ်ဂှ် တင်ဂၞင်သုတေသန မပလဝ် ပ္ဍဲအခိင်ယဲသာဂှ် ဒှ်အထံက်အရီုရောင် သွက််ဂွံကၠောန်ဗဒှ် ဝက်သိန်ရောင်ဂှ် စၟဳကေတ်လဝ်ကီုရ။<ref name="JiangFutureVirology" /><ref name="Butler3oct2013">{{cite journal|vauthors=Butler D|date=October 2012|title=SARS veterans tackle coronavirus|journal=Nature|volume=490|issue=7418|page=20|bibcode=2012Natur.490...20B|doi=10.1038/490020a|pmid=23038444|doi-access=free}}</ref> ၜိုတ်ဂိတုမာတ် ၂၀၂၀ ဂှ် ဝက်သိန်ယဲမာလဵုမွဲလေဝ် ဟွံစိုပ်ကဆံင် ကာလစွမ်ပထမ သွက်ဂွံစမ်မၞိဟ်ဏီ၊<ref>{{cite journal|display-authors=6|vauthors=Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN|date=September 2019|title=Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial|journal=The Lancet. Infectious Diseases|volume=19|issue=9|pages=1013–22|doi=10.1016/S1473-3099(19)30266-X|pmc=7185789|pmid=31351922|doi-access=free}}</ref> တုဲပၠန် ဂဥုဲတၞဟ်ပိဂှ် ဒှ်အခိင်အဃောမကၠောန်ဗဒှ် ဇၞော်ပၟဝ်ဒၟံင်၊ သီုပိဂှ် ၜါဂှ် ChAdOx1-MERS, BVRS-GamVac တုဲ မွဲဂှ် MVA-MERS-S။<ref>{{cite journal|vauthors=Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS|year=2019|title=Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus|journal=Frontiers in Microbiology|volume=10|page=1781|doi=10.3389/fmicb.2019.01781|pmc=6688523|pmid=31428074}}</ref>

===Early development===
After the coronavirus was detected in December 2019,<ref name="who-time">{{Cite web|date=27 April 2020|title=World Health Organization timeline – COVID-19|url=https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19|url-status=live|archive-url=https://web.archive.org/web/20200429012212/https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19|archive-date=29 April 2020|access-date=2 May 2020|publisher=World Health Organization}}</ref> the [[Nucleic acid sequence|genetic sequence]] of COVID‑19 was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten development of a preventive vaccine.<ref name="thanh" /><ref name="gates1" /><ref name="Fauci">{{cite journal|vauthors=Fauci AS, Lane HC, Redfield RR|date=March 2020|title=Covid-19: Navigating the uncharted|journal=The New England Journal of Medicine|volume=382|issue=13|pages=1268–69|doi=10.1056/nejme2002387|pmc=7121221|pmid=32109011}}</ref>

In February 2020, the [[World Health Organization]] (WHO) said it did not expect a vaccine against [[severe acute respiratory syndrome coronavirus 2]] (SARS-CoV-2), the causative virus, to become available in less than 18 months.<ref>{{cite web|last1=Grenfell|first1=Rob|last2=Drew|first2=Trevor|date=14 February 2020|title=Here's why the WHO says a coronavirus vaccine is 18 months away|url=https://theconversation.com/heres-why-the-who-says-a-coronavirus-vaccine-is-18-months-away-131213|access-date=11 November 2020|website=Business Insider|name-list-style=vanc}}</ref> The rapidly growing infection rate of COVID‑19 worldwide during early 2020 stimulated international alliances and government efforts to urgently organize resources to make multiple vaccines on shortened timelines,<ref name="who-accel">{{Cite web|date=27 April 2020|title=Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine|url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine|url-status=live|archive-url=https://web.archive.org/web/20200430185550/https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine|archive-date=30 April 2020|access-date=2 May 2020|publisher=World Health Organization|quote=It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.}}</ref> with four vaccine candidates entering human evaluation in March (see the table of [[#Clinical trials started in 2020|clinical trials started in 2020]], below).<ref name="thanh" /><ref name="yamey" />

In April 2020, the WHO estimated a total cost of {{US$|8}}{{nbsp}}billion to develop a suite of three or more vaccines having different technologies and distribution.<ref name="who-accel" />

By April 2020, "almost 80 companies and institutes in 19 countries" were working on this virtual gold rush.<ref name="cssa">{{cite news|last1=Schmidt|first1=Charles|date=1 June 2020|title=Genetic Engineering Could Make a COVID-19 Vaccine in Months Rather Than Years|work=Scientific American|url=https://www.scientificamerican.com/article/genetic-engineering-could-make-a-covid-19-vaccine-in-months-rather-than-years1/|url-status=live|access-date=26 August 2020|archive-url=https://web.archive.org/web/20201011084737/https://www.scientificamerican.com/article/genetic-engineering-could-make-a-covid-19-vaccine-in-months-rather-than-years1//|archive-date=11 October 2020|name-list-style=vanc}}</ref> Also in April, CEPI estimated that as many as six of the vaccine candidates against COVID‑19 should be chosen by international coalitions for development through Phase{{nbsp}}II–III trials, and three should be streamlined through regulatory and quality assurance for eventual licensing at a total cost of at least {{US$|2}}{{nbsp}}billion.<ref name="thanh2" /><ref name="yamey" /><ref name="gates2" /> Another analysis estimates 10 candidates will need simultaneous initial development, before a select few are chosen for the final path to licensing.<ref name="gates2" />

In July 2020, Anglo-American intelligence and security organisations of the respective governments and armed forces, as the UK's [[National Cyber Security Centre (United Kingdom)|National Cyber Security Centre]], together with the Canadian [[Communications Security Establishment]], the United States Department for Homeland Security [[Cybersecurity and Infrastructure Security Agency|Cybersecurity Infrastructure Security Agency]], and the US [[National Security Agency]] (NSA) alleged that Russian state-backed hackers may have been trying to steal COVID‑19 treatment and vaccine research from academic and pharmaceutical institutions in other countries; Russia has denied it.<ref>{{Cite news|last1=Fox|first1=Chris|last2=Kelion|first2=Leo|date=16 July 2020|title=Russian spies 'target coronavirus vaccine'|work=BBC News Online|url=https://www.bbc.com/news/technology-53429506|url-status=live|access-date=1 August 2020|archive-url=https://web.archive.org/web/20201011084740/https://www.bbc.com/news/technology-53429506/|archive-date=11 October 2020|name-list-style=vanc}}</ref>

===Preclinical research===
In April 2020, the WHO issued a statement representing dozens of vaccine scientists around the world, pledging collaboration to speed development of a vaccine against COVID‑19.<ref name="who-scientists">{{Cite web|date=13 April 2020|title=Public statement for collaboration on COVID-19 vaccine development|url=https://www.who.int/news-room/detail/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development|url-status=live|archive-url=https://web.archive.org/web/20200420214124/https://www.who.int/news-room/detail/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development|archive-date=20 April 2020|access-date=20 April 2020|publisher=World Health Organization}}</ref> The WHO coalition is encouraging international cooperation between organizations developing vaccine candidates, national regulatory and policy agencies, financial contributors, public health associations, and governments, for eventual manufacturing of a successful vaccine in quantities sufficient to supply all affected regions, particularly low-resource countries.<ref name="thanh" />

Industry analysis of past vaccine development shows failure rates of 84–90%.<ref name="thanh" /><ref name="bio" /> Because COVID‑19 is a novel virus target with properties still being discovered and requiring innovative vaccine technologies and development strategies, the risks associated with developing a successful vaccine across all steps of preclinical and clinical research are high.<ref name="thanh" />

To assess potential for vaccine efficacy, unprecedented computer simulations and new COVID‑19-specific animal models are being developed multinationally during 2020, but these methods remain untested by unknown characteristics of the COVID‑19 virus.<ref name="thanh" /> Of the confirmed active vaccine candidates, about 70% are being developed by private companies, with the remaining projects under development by academic, government coalitions, and health organizations.<ref name="thanh2" />

Most of the vaccine developers are small firms or university research teams with little experience in successful vaccine design and limited capacity for advanced clinical trial costs and manufacturing without partnership by multinational pharmaceutical companies.<ref name="thanh2" /><ref name="thanh" />

Historically, the probability of success for an infectious disease vaccine candidate to pass preclinical barriers and reach Phase{{nbsp}}I of human testing is 41–57%.<ref name="gouglas" />

===Technology platforms===
[[File:Vaccine candidate mechanisms for SARS-CoV-2 (49948301838).jpg|thumb|400px|Potential candidates for forming SARS-CoV-2 proteins to prompt an immune response]]
<!-- FIRST PARAGRAPH TRANSCLUDED INTO VACCINE SECTION OF CORONAVIRUS DISEASE 2019 TOPIC -->
As of September 2020, nine different technology platforms{{spaced ndash}}with the technology of numerous candidates remaining undefined{{spaced ndash}}were under research and development to create an effective vaccine against COVID‑19.<ref name="thanh2" /> Most of the platforms of vaccine candidates in clinical trials are focused on the [[Coronavirus#Microbiology|coronavirus spike protein and its variants]] as the primary [[antigen]] of COVID‑19 infection.<ref name="thanh2" /> Platforms being developed in 2020 involved [[nucleic acid]] technologies ([[nucleoside-modified messenger RNA]] and [[DNA]]), [[Viral vector#Vaccines|non-replicating viral vectors]], [[peptide]]s, [[recombinant protein]]s, live [[attenuated virus]]es, and [[Virus processing#Viral inactivation|inactivated viruses]].<ref name="gates2" /><ref name="thanh">{{cite journal | last1=Thanh Le | first1=Tung | last2=Andreadakis | first2=Zacharias | last3=Kumar | first3=Arun | last4=Gómez Román | first4=Raúl | last5=Tollefsen | first5=Stig | last6=Saville | first6=Melanie | last7=Mayhew | first7=Stephen | display-authors=6 | title=The COVID-19 vaccine development landscape | journal=Nature Reviews Drug Discovery | date=9 April 2020 | volume=19 | issue=5 | pages=305–06 | issn=1474-1776 | doi=10.1038/d41573-020-00073-5 | pmid=32273591 | doi-access=free | name-list-style=vanc }}</ref><ref name="thanh2" /><ref name="diamond">{{Cite journal|last1=Diamond|first1=Michael S|last2=Pierson|first2=Theodore C|date=13 May 2020|title=The challenges of vaccine development against a new virus during a pandemic|journal=Cell Host and Microbe|volume=27|issue=5|pages=699–703|doi=10.1016/j.chom.2020.04.021|pmc=7219397|pmid=32407708|name-list-style=vanc}}</ref>

Many vaccine technologies being developed for COVID‑19 are not like vaccines already in use to prevent influenza, but rather are using "next-generation" strategies for precision on COVID‑19 infection mechanisms.<ref name=thanh/><ref name=thanh2/><ref name=diamond/> Vaccine platforms in development may improve flexibility for antigen manipulation and effectiveness for targeting mechanisms of COVID‑19 infection in susceptible population subgroups, such as healthcare workers, the elderly, children, pregnant women, and people with existing weakened [[immune system]]s.<ref name=thanh/><ref name=thanh2/><!-- From 2nd source: It is conceivable that some vaccine platforms may be better suited to specific population subtypes (such as the elderly, children, pregnant women or immunocompromised patients). -->
<noinclude>

{| class="wikitable" style="text-align: right;"
|+COVID‑19 vaccine technology platforms, December 2020<ref name="london">{{cite web|date=16 December 2020|title=COVID-19 vaccine development pipeline (Refresh URL to update)|url=https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/|access-date=18 December 2020|publisher=Vaccine Centre, London School of Hygiene and Tropical Medicine}}</ref>
|-
! Molecular platform{{efn-lr|Technologies for dozens of candidates are unannounced or "unknown".<ref name=london/>}}
! Total number <br />of candidates
! Number of candidates <br />in human trials
|-
| {{Left}} Inactivated virus
| <center>19</center>
| <center>5{{efn-lr|name="phase2orhigher"}}</center>
|-
| {{Left}} Non-replicating viral vector
| <center>35</center>
| <center>4{{efn-lr|name="phase2orhigher"|One or more candidates in Phase II or Phase II–III trials.}}</center>
|-
| {{Left}} RNA-based
| <center>36</center>
| <center>3{{efn-lr|name="phase2orhigher"}}</center>
|-
| {{Left}} Protein subunit
| <center>80</center>
| <center>2{{efn-lr|name="phase2orhigher"}}</center>
|-
| {{Left}} DNA-based
| <center>23</center>
| <center>2{{efn-lr|name="phase2orhigher"}}</center>
|-
| {{Left}} Virus-like particle
| <center>19</center>
| <center>1{{efn-lr|name="phase2orhigher"}}</center>
|-
| {{Left}} Replicating viral vector
| <center>23</center>
| <center>0</center>
|-
| {{Left}} Live attenuated virus
| <center>4</center>
| <center>0</center>
|-
|}
{{notelist-lr}}

===Challenges===
The rapid development and urgency of producing a vaccine for the COVID‑19 pandemic may increase the risks and failure rate of delivering a safe, effective vaccine.<ref name=diamond/><ref name=thanh/><ref name="Thorp">{{cite journal |last1=Thorp |first1=H. Holden |title=Underpromise, overdeliver |journal=Science |date=27 March 2020 |volume=367 |issue=6485 |page=1405 |doi=10.1126/science.abb8492 |pmid=32205459 |bibcode=2020Sci...367.1405T |doi-access=free | name-list-style = vanc }}</ref> One study found that between 2006 and 2015, the success rate of obtaining approval from Phase{{nbsp}}I to successful Phase{{nbsp}}III trials was 16.2% for vaccines,<ref name="bio">{{cite web|url=https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf|title=Clinical Development Success Rates 2006–2015|date=June 2016|publisher=BIO Industry Analysis|access-date=23 March 2020|archive-url=https://web.archive.org/web/20190912220246/https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf|archive-date=12 September 2019|url-status=live}}</ref> and CEPI indicates a potential success rate of only 10% for vaccine candidates in 2020 development.<ref name=thanh/>

An April 2020 CEPI report stated: "Strong international coordination and cooperation between vaccine developers, regulators, policymakers, funders, public health bodies and governments will be needed to ensure that promising late-stage vaccine candidates can be manufactured in sufficient quantities and equitably supplied to all affected areas, particularly low-resource regions."<ref name=thanh/>

====Biosafety====
Early research to assess vaccine efficacy using COVID‑19-specific animal models, such as [[ACE2]]-[[transgenic]] mice, other laboratory animals, and non-human primates, indicates a need for [[biosafety]]-level{{nbsp}}3 containment measures for handling live viruses, and international coordination to ensure standardized safety procedures.<ref name=diamond/><ref name=thanh/>

====Antibody-dependent enhancement====
{{main|Antibody-dependent enhancement}}
Although the quality and quantity of [[antibody]] production by a potential vaccine is intended to neutralize the COVID‑19 infection, a vaccine may have an unintended opposite effect by causing [[antibody-dependent enhancement|antibody-dependent disease enhancement]] (ADE), which increases the virus attachment to its target cells and might trigger a [[cytokine storm]] if a vaccinated person is later attacked by the virus.<ref name=diamond/><ref name="iwasaki">{{Cite journal|last1=Iwasaki|first1=Akiko|last2=Yang|first2=Yexin|date=21 April 2020|title=The potential danger of suboptimal antibody responses in COVID-19|journal=Nature Reviews Immunology|volume=20|issue=6|pages=339–41|doi=10.1038/s41577-020-0321-6|issn=1474-1733|pmc=7187142|pmid=32317716 | name-list-style = vanc }}</ref> The vaccine technology platform (for example, [[viral vector]] vaccine, [[Severe acute respiratory syndrome-related coronavirus#Morphology|spike (S) protein]] vaccine or [[protein subunit]] vaccine), vaccine dose, timing of repeat vaccinations for the possible recurrence of COVID‑19 infection, and elderly age are factors determining the risk and extent of ADE.<ref name=diamond/><ref name=iwasaki/> The antibody response to a vaccine is a variable of vaccine technologies in development, including whether the vaccine has precision in its mechanism,<ref name=diamond/> and choice of the route for how it is given ([[Intramuscular injection|intramuscular]], [[Intradermal injection|intradermal]], oral, or nasal).<ref name=iwasaki/>

====Cost====

An effective vaccine for COVID‑19 could save [[trillion]]s of dollars in global economic impact, according to one expert, and would, therefore, make any price tag in the billions look small in comparison.<ref name="gates3">{{Cite web|title=The first modern pandemic: The scientific advances we need to stop COVID-19|url=https://www.gatesnotes.com/Health/Pandemic-Innovation|last=Gates|first=Bill |date=23 April 2020|publisher=The Gates Notes|access-date=6 May 2020|archive-url= https://web.archive.org/web/20200513122415/https://www.gatesnotes.com/Health/Pandemic-Innovation |archive-date=13 May 2020|url-status=live | name-list-style=vanc }}</ref> In early stages of the pandemic, it was not known if it would be possible to create a safe, reliable and affordable vaccine for this virus, and it was not known exactly how much the vaccine development could cost.<ref name=gates2/><ref name=gates1/><ref name=sanger/> There was a possibility that billions of dollars could be invested without success.<ref name=reuters/>

Once an effective vaccine would be developed, billions of doses would need to be manufactured and distributed worldwide. In April 2020, the Gates Foundation estimated that manufacturing and distribution could cost as much as {{US$|25}}{{nbsp}}billion.<ref>{{Cite news|title=Global philanthropists, experts call for COVID-19 vaccine distribution plan|url=https://www.thestar.com/news/canada/2020/04/30/global-philanthropists-experts-call-for-covid-19-vaccine-distribution-plan.html |date=30 April 2020|first=Mike|last=Blanchfield |work=The Toronto Star|access-date=6 May 2020|archive-url= https://web.archive.org/web/20200507230428/https://www.thestar.com/news/canada/2020/04/30/global-philanthropists-experts-call-for-covid-19-vaccine-distribution-plan.html |archive-date=7 May 2020|url-status=live | name-list-style=vanc }}</ref> On 4 May 2020, the European Commission organized and held a video conference of world leaders, at which {{US$|8}}{{nbsp}}billion was raised for COVID‑19 vaccine development.<ref>{{Cite news|last1=Stevis-Gridneff|first1=Matina |last2=Jakes|first2=Lara|date=4 May 2020|title=World Leaders Join to Pledge $8 Billion for Vaccine as U.S. Goes It Alone|work=[[The New York Times]]|url=https://www.nytimes.com/2020/05/04/world/europe/eu-coronavirus-vaccine.html |access-date=10 May 2020|issn=0362-4331|archive-url= https://web.archive.org/web/20200513041549/https://www.nytimes.com/2020/05/04/world/europe/eu-coronavirus-vaccine.html |archive-date=13 May 2020|url-status=live | name-list-style = vanc }}</ref>

As of November 2020, companies subsidized under the United States' Operation Warp Speed program have set initial pricing at {{US$|19.50}} to {{US$|25}} per dose, in line with the [[influenza vaccine]].<ref>{{Cite web|last=Jennings|first=Katie |date=17 November 2020|title=How Much Will A Covid-19 Vaccine Cost?|url=https://www.forbes.com/sites/katiejennings/2020/11/17/how-much-will-a-covid-19-vaccine-cost/ |access-date=6 December 2020|website=Forbes}}</ref> In December 2020, a Belgian politician briefly published the confidential prices agreed between vaccine producers and the EU:<ref>{{cite web |title=European vaccine prices revealed in Belgian Twitter blunder |url=https://www.brusselstimes.com/news/belgium-all-news/146038/european-vaccine-prices-revealed-in-belgian-twitter-blunder-n-va-covid-19-eva-de-bleeker-open-vld-pfizer-biontech-astra-zeneca-sanofi-gsk-johnson-moderna-curevac-peter-de-roover-frank-vandenbroucke/ |website=[[The Brussels Times]] |language=en |date=18 December 2020}}</ref>
{| class="wikitable sortable"
!Manufacturer
!EU price per dose<ref>{{Cite web|last=Bossaert|first=Jeroen|date=2020-12-17|title=Zoveel gaan we betalen voor de coronavaccins: staatssecretaris zet confidentiële prijzen per ongeluk online|url=https://www.hln.be/binnenland/zoveel-gaan-we-betalen-voor-de-coronavaccins-staatssecretaris-zet-confidentiele-prijzen-per-ongeluk-online~a3dceef4/|access-date=18 December 2020|website=[[Het Laatste Nieuws]]}}</ref>
|-
|AstraZeneca
|{{Euro|1.78}}
|-
|Johnson&Johnson
|{{US$|8.50}}
|-
|Sanofi/GSK
|{{Euro|7.56}}
|-
|Pfizer/BioNTech
|{{Euro|12.00}}
|-
|CureVac
|{{Euro|10.00}}
|-
|Moderna
|{{US$|18.00}}
|}

==== Rollout ====
{{See also|COVID-19 vaccination programme in the United Kingdom}}
Different vaccines have different shipping and handling requirements. For example, the Pfizer/BioNTech vaccine [[tozinameran]] (Pfizer-BioNTech COVID-19 Vaccine) must be shipped and [[ULT freezer|stored]] between {{Convert|-80|and|-60|C|F|abbr=}},<ref name="Vaccination Storage">{{cite web | title=Pfizer-BioNTech COVID-19 Vaccine Vaccination Storage & Dry Ice Safety Handling | publisher=Pfizer | url=https://www.cvdvaccine-us.com/product-storage-and-dry-ice | access-date=17 December 2020}}</ref> must be used within five days of thawing,<ref name="Vaccination Storage" /> and has a minimum order of 975 doses, making it unlikely to be rolled out in settings other than large, well-equipped hospitals.<ref>{{Cite web|date=9 October 2020|title=7 looming questions about the rollout of a Covid-19 vaccine|url=https://www.statnews.com/2020/10/09/7-looming-questions-about-the-rollout-of-a-covid-19-vaccine/|access-date=10 October 2020|website=[[Stat (website)|Stat]]|archive-date=10 October 2020|archive-url=https://web.archive.org/web/20201010225321/https://www.statnews.com/2020/10/09/7-looming-questions-about-the-rollout-of-a-covid-19-vaccine/|url-status=live}}</ref> The Moderna COVID-19 Vaccine vials require storage above {{convert|-40|C|F}} and between {{convert|-25|and|-15|C|F}}.<ref name="Moderna fact sheet">{{cite web | url=https://www.fda.gov/media/144637/download | format=PDF | title=Fact Sheet for Healthcare Providers Administering Vaccine | publisher=ModernaTX, Inc.}}</ref> Once refrigerated, the Moderna COVID-19 Vaccine can be kept between {{convert|2|and|8|C|F}} for up to 30 days.<ref name="Moderna fact sheet" />

===Trials===
[[File:Covid vaccine clinical trial, Padjajaran University (cropped).jpg|thumb|Volunteer receives CoronaVac injection during Phase III trial by Sinovac in Indonesia.]]
In April 2020, the WHO published an "R&D Blueprint (for the) novel Coronavirus" (Blueprint). The Blueprint documented a "large, international, multi-site, individually randomized controlled clinical trial" to allow "the concurrent evaluation of the benefits and risks of each promising candidate vaccine within 3–6 months of it being made available for the trial." The Blueprint listed a ''Global Target Product Profile'' (TPP) for COVID‑19, identifying favorable attributes of safe and effective vaccines under two broad categories: "vaccines for the long-term protection of people at higher risk of COVID‑19, such as healthcare workers", and other vaccines to provide rapid-response immunity for new outbreaks.<ref name="who-accel" /> The international TPP team was formed to 1) assess the development of the most promising candidate vaccines; 2) map candidate vaccines and their clinical trial worldwide, publishing a frequently-updated "landscape" of vaccines in development;<ref name="who-tracker">{{Cite web|date=10 December 2020|title=Draft landscape of COVID 19 candidate vaccines|url=https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines|access-date=11 December 2020|publisher=World Health Organization}}</ref> 3) rapidly evaluate and screen for the most promising candidate vaccines simultaneously before they are tested in humans; and 4) design and coordinate a multiple-site, international [[randomized controlled trial]]{{snd}}the "Solidarity trial" for vaccines<ref name="who-accel" /><ref name="solidarity-vacc">{{Cite web|date=9 April 2020|title=An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial|url=https://www.who.int/blueprint/priority-diseases/key-action/Outline_CoreProtocol_vaccine_trial_09042020.pdf|url-status=live|archive-url=https://web.archive.org/web/20200512115627/https://www.who.int/blueprint/priority-diseases/key-action/Outline_CoreProtocol_vaccine_trial_09042020.pdf|archive-date=12 May 2020|access-date=9 May 2020|publisher=World Health Organization}}</ref>{{snd}}to enable simultaneous evaluation of the benefits and risks of different vaccine candidates under clinical trials in countries where there are high rates of COVID‑19 disease, ensuring fast interpretation and sharing of results around the world.<ref name="who-accel" /> The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials, and determine harmonized Phase{{nbsp}}III protocols for all vaccines achieving the [[pivotal trial]] stage.<ref name="who-accel" />

====Enrollment of participants====

Vaccine developers have to invest resources internationally to find enough participants for Phase{{nbsp}}II–III clinical trials when the virus has proved to be a "[[Moving target indication|moving target]]" of changing transmission rate across and within countries, forcing companies to compete for trial participants.<ref name="cohen6-19">{{cite journal|journal=Science|title=Pandemic vaccines are about to face the real test|volume=368|issue=6497|pages=1295–96|doi=10.1126/science.368.6497.1295|last=Cohen | first=Jon |date=19 June 2020|pmid=32554572|bibcode=2020Sci...368.1295C|doi-access=free | name-list-style=vanc }}</ref> As an example in June, the Chinese vaccine developer Sinovac formed alliances in [[Malaysia]], Canada, the UK, and Brazil among its plans to recruit trial participants and manufacture enough vaccine doses for a possible Phase{{nbsp}}III study in Brazil where COVID‑19 transmission was accelerating during June.<ref name=cohen6-19/> As the COVID‑19 pandemic within China became more isolated and controlled, Chinese vaccine developers sought international relationships to conduct advanced human studies in several countries, creating competition for trial participants with other manufacturers and the international Solidarity trial organized by the WHO.<ref name=cohen6-19/> In addition to competition over recruiting participants, clinical trial organizers may encounter people unwilling to be vaccinated due to [[vaccine hesitancy]]<ref name="dube">{{Cite journal|last1=Dubé|first1=Eve|last2=Laberge|first2=Caroline|last3=Guay|first3=Maryse|last4=Bramadat|first4=Paul|last5=Roy|first5=Réal|last6=Bettinger|first6=Julie|date=1 August 2013|title=Vaccine hesitancy: an overview|journal=Human Vaccines and Immunotherapeutics|volume=9|issue=8|pages=1763–73|doi=10.4161/hv.24657|issn=2164-554X|pmc=3906279|pmid=23584253|name-list-style=vanc}}</ref> or disbelieving the science of the vaccine technology and its ability to prevent infection.<ref name="howard-cnn">{{cite news |first1=Jacqueline | last1=Howard |first2=Veronica | last2=Stracqualursi |title=Fauci warns of 'anti-science bias' being a problem in US |url=https://www.cnn.com/2020/06/18/politics/anthony-fauci-coronavirus-anti-science-bias/index.html |access-date=21 June 2020 |work=CNN |date=18 June 2020 |archive-url=https://web.archive.org/web/20200621003117/https://www.cnn.com/2020/06/18/politics/anthony-fauci-coronavirus-anti-science-bias/index.html |archive-date=21 June 2020 |url-status=live | name-list-style = vanc }}</ref>

Having an insufficient number of skilled team members to administer vaccinations may hinder clinical trials that must overcome risks for trial failure, such as recruiting participants in rural or low-density geographic regions, and variations of age, race, ethnicity, or underlying medical conditions.<ref name=cohen6-19/><ref name="winter">{{cite journal | last1=Winter | first1=SS | last2=Page-Reeves | first2=JM | last3=Page | first3=KA | last4=Haozous | first4=E | last5=Solares | first5=A | last6=Nicole Cordova | first6=C | last7=Larson | first7=RS | title=Inclusion of special populations in clinical research: important considerations and guidelines|type=Review | journal=Journal of Clinical and Translational Research | volume=4 | issue=1 | date=28 May 2018 | issn=2382-6533 | pmid=30873495 | pmc=6410628 | pages=56–69 | name-list-style=vanc }}</ref>

====Adaptive design for the Solidarity trial====
A clinical trial design in progress may be modified as an [[adaptive design (medicine)|"adaptive design"]] if accumulating data in the trial provide early insights about positive or negative efficacy of the treatment.<ref name="pallmann">{{cite journal|display-authors=6|vauthors=Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JM, Weir CJ, Wheeler GM, Yap C, Jaki T|date=February 2018|title=Adaptive designs in clinical trials: why use them, and how to run and report them|journal=BMC Medicine|volume=16|issue=1|page=29|doi=10.1186/s12916-018-1017-7|pmc=5830330|pmid=29490655}}</ref><ref name="fda-adaptive">{{cite web|date=1 November 2019|title=Adaptive designs for clinical trials of drugs and biologics: Guidance for industry|url=https://www.fda.gov/media/78495/download|url-status=live|archive-url=https://web.archive.org/web/20191213234438/https://www.fda.gov/media/78495/download|archive-date=13 December 2019|access-date=3 April 2020|publisher=U.S. [[Food and Drug Administration]] (FDA)}}</ref> The WHO Solidarity trial of multiple vaccines in clinical studies during 2020, will apply adaptive design to rapidly alter trial parameters across all study sites as results emerge.<ref name="solidarity-vacc" /> Candidate vaccines may be added to the Solidarity trial as they become available if priority criteria are met, while vaccine candidates showing poor evidence of safety or efficacy compared to placebo or other vaccines will be dropped from the international trial.<ref name="solidarity-vacc" />

Adaptive designs within ongoing Phase{{nbsp}}II–III clinical trials on candidate vaccines may shorten trial durations and use fewer subjects, possibly expediting decisions for early termination or success, avoiding duplication of research efforts, and enhancing coordination of design changes for the Solidarity trial across its international locations.<ref name="solidarity-vacc" /><ref name="pallmann" />

====Proposed challenge studies====
{{main|Human challenge study}}

[[Human challenge study|Challenge studies]] are a type of clinical trial involving the intentional exposure of the test subject to the condition tested, an approach that can significantly accelerate vaccine development.<ref name="lamb">{{Cite journal|last1=Lambkin-Williams|first1=Rob|last2=Noulin|first2=Nicolas|last3=Mann|first3=Alex|last4=Catchpole|first4=Andrew|last5=Gilbert|first5=Anthony S.|date=2018-06-22|title=The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics|journal=Respiratory Research|volume=19|issue=1|pages=123|doi=10.1186/s12931-018-0784-1|issn=1465-993X|pmc=6013893|pmid=29929556}}</ref><ref name="eyal">{{Cite journal|last1=Eyal|first1=Nir|last2=Lipsitch|first2=Marc|last3=Smith|first3=Peter G.|title=Human challenge studies to accelerate coronavirus vaccine licensure|url=https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216|journal=The Journal of Infectious Diseases|doi=10.1093/infdis/jiaa152|date=31 March 2020|volume=221|issue=11|pages=1752–1756|pmid=32232474|pmc=7184325| name-list-style = vanc }}</ref><ref name="callaway">{{Cite journal|vauthors=Callaway E |date=April 2020|title=Should scientists infect healthy people with the coronavirus to test vaccines?|url=https://www.nature.com/articles/d41586-020-00927-3|journal=Nature|volume=580|issue=7801|pages=17|doi=10.1038/d41586-020-00927-3|pmid=32218549|bibcode=2020Natur.580...17C|doi-access=free}}</ref><ref name="cohen" /> Human challenge studies may be ethically controversial because they involve exposing test subjects to dangers beyond those posed by potential [[side effect]]s of the substance being tested.<ref name=eyal/><ref name=callaway/> Challenge studies have been used for diseases less deadly than COVID‑19 infection, such as common influenza, [[typhoid fever]], [[cholera]], and [[malaria]].<ref name="callaway" /><ref name="cohen">{{Cite journal|last=Cohen|first=Jon|date=31 March 2020|title=Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn|journal=Science|doi=10.1126/science.abc0006|doi-access=free|name-list-style=vanc}}</ref> The World Health Organization has developed a guidance document with criteria for conducting COVID‑19 challenge studies in healthy people, including scientific and ethical evaluation, public consultation and coordination, selection and [[informed consent]] of the participants, and monitoring by independent experts.<ref name="who-challenge">{{Cite web|date=6 May 2020|title=Key criteria for the ethical acceptability of COVID-19 human challenge studies|url=https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf|url-status=live|archive-url=https://web.archive.org/web/20200508153855/https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf|archive-date=8 May 2020|access-date=12 May 2020|publisher=World Health Organization}}</ref> Beginning in January 2021, dozens of young adult volunteers will be deliberately infected with COVID‑19 in a challenge trial conducted in a London hospital under management by the British government COVID-19 Vaccine Taskforce.<ref name="call-challenge">{{cite journal|last1=Callaway|first1=Ewen|date=20 October 2020|title=Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials|journal=Nature|volume=586|issue=7831|pages=651–652|doi=10.1038/d41586-020-02821-4|pmid=33082550|doi-access=free|name-list-style=vanc|s2cid=224823112}}</ref> Once an infection dose of COVID‑19 is identified, two or more of the candidate COVID-19 vaccines will be tested for effectiveness in preventing infection.<ref name="call-challenge" />

==နိဿဲ==
{{reflist}}

==Footnotes==
{{notelist}}

==Further reading==
* {{cite book|last=Vogel|first=Patric U. B.|date=2020|title=COVID-19 : Suche nach einem Impfstoff|series=Essentials|url=https://link.springer.com/book/10.1007/978-3-658-31340-1|location=Wiesbaden|publisher=Springer Fachmedien Wiesbaden GmbH|doi=10.1007/978-3-658-31340-1|isbn=978-3-658-31340-1|oclc=1199717422}}
* {{cite journal |vauthors=Funk CD, Laferrière C, Ardakani A |title=A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic |journal=Front Pharmacol |volume=11 |page=937 |date=2020 |pmid=32636754 |pmc=7317023 |doi=10.3389/fphar.2020.00937 |doi-access=free}}
* {{cite web | last1=Johnson | first1=Carolyn Y. | last2=Mufson | first2=Steven | name-list-style = vanc | title=Can old vaccines from science's medicine cabinet ward off coronavirus? | website=[[The Washington Post]] | date=11 June 2020 | url=https://www.washingtonpost.com/health/2020/06/11/can-old-vaccines-sciences-medicine-cabinet-ward-off-coronavirus/ }}
* {{cite document | title=Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry | url=https://www.fda.gov/media/139638/download | format=PDF | publisher=U.S. [[Food and Drug Administration]] (FDA) | date=June 2020 | lay-url=https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19 }}
* {{cite web | first1=Carl | last1=Zimmer | first2=Knvul | last2=Sheikh | first3=Noah | last3=Weiland | name-list-style = vanc | title=A New Entry in the Race for a Coronavirus Vaccine: Hope | website=[[The New York Times]] | date=20 May 2020 | url=https://www.nytimes.com/2020/05/20/health/coronavirus-vaccines.html }}
*{{Cite web|last=Haelle|first=Tara|date=12 December 2020|title=Every Covid-19 Vaccine Question You'll Ever Have, Answered|url=https://elemental.medium.com/every-covid-19-vaccine-question-youll-ever-have-answered-9a0eeb334ded|access-date=12 December 2020|website=Medium}}

==External links==
{{Wikiquote}}
* {{cite web | title=Coronavirus Vaccine Tracker | website=[[The New York Times]] | url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html }}
* [https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker COVID-19 vaccine tracker, Regulatory Focus]
* {{cite web | title=STAT's Covid-19 Drugs and Vaccines Tracker | work=[[Stat (website)|Stat]] | url=https://www.statnews.com/feature/coronavirus/drugs-vaccines-tracker/#vaccines }}
* {{cite press release | title=Biopharma Leaders Unite to Stand with Science | via=[[Business Wire]] | date=8 September 2020 | url=https://www.businesswire.com/news/home/20200908005282/en/ }}
* {{cite web | url=https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf | title=Protocol mRNA-1273-P301 | publisher=[[Moderna]] }}
* {{cite web | url=https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf | title=Protocol C4591001 PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) | publisher=[[Pfizer]] }}
* {{cite web | url=https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf | title=Protocol AZD1222 – D8110C00001 | publisher=[[AstraZeneca]] }}
* {{cite web | url=https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol | format=PDF | title=Protocol VAC31518COV3001; Phase 3 | publisher=[[Janssen Pharmaceutica|Janssen Vaccines & Prevention]] }}
* {{cite web | last=Levine | first=Hallie | title=The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works | publisher=Johnson & Johnson | date=23 September 2020 | url=https://www.jnj.com/innovation/the-5-stages-of-covid-19-vaccine-development-what-you-need-to-know-about-how-a-clinical-trial-works }}
* {{cite web | title=COVID-19 vaccines: development, evaluation, approval and monitoring | publisher=[[European Medicines Agency]] | url=https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring }}
* {{cite web | title=Vaccine Development – 101 | publisher=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/vaccine-development-101 }}


[[Category:ပရေင်ထတ်ယုက်]]
[[Category:BEHM]]
